Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tobramycin + sodium calcium edetate
- Development stage
- Phase 2
- Lead developer
- Respirion Pharmaceuticals
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
RSP-1502 is an inhaled combination drug consisting of tobramycin (an aminoglycoside antibiotic) and sodium calcium edetate (calcium EDTA), developed as a novel treatment for respiratory infections in people with cystic fibrosis. The drug acts as an "antibiotic booster," aiming to enhance the effectiveness of standard antibiotic therapy against chronic lung infections caused by *Pseudomonas aeruginosa*. The mechanism involves both inhibition of bacterial protein synthesis via the 30S ribosomal subunit (tobramycin) and chelation of divalent cations that can disrupt biofilms or bacterial defenses (calcium EDTA). Early clinical trials have shown significant reductions in bacterial load and improvements in lung function compared to standard care. RSP-1502 is being developed by Respirion Pharmaceuticals, a spin-out from Telethon Kids Institute and Perth Children's Hospital, with support from Brandon Capital and the US Cystic Fibrosis Foundation[1][3][4][5].
- Other names
- Tobramycin + Calcium EDTATobramycin + Sodium calcium edetateTobramycin + Calcium EDTA combination therapyTobramycin + Sodium calcium edetate combination therapy
02
Targets
30S A-site (Bacterial ribosomal 30S A-site)Extracellular divalent cations
Beyond the preview
Go deeper on tobramycin + sodium calcium edetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tobramycin + sodium calcium edetate.